Skip to content
Disclosery

TCG Crossover Management, LLC

Follow

13F filer, CIK 1839948, PALO ALTO, CA

TCG Crossover Management, LLC reported $4,160,526,316 across 54 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 57.45% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001214659-26-010290

Period
2026-06-30
Reported value
$4.16B
Holdings
54
Top 10 weight
57.45%
New
12
Sold out
7

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ZLABnew+6,137,627$117M
AURAnew+9,533,333$67.7M
TRAXnew+2,895,304$58.3M
AVTXadded+2,278,737$42.1M
EDITnew+11,111,111$36M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CNTAexited-4,286,480-$170M
ABVXreduced-473,251-$63.1M
TNGXreduced-1,449,870-$45.3M
RVMDreduced-235,574-$44.1M
BHVNreduced-2,851,365-$42.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001214659-26-010290, largest first. % of portfolio is the value over $4,160,526,316, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 6,056,596 shares; 2024Q4: 6,056,596 shares; 2025Q1: 6,056,596 shares; 2025Q2: 6,056,596 shares; 2025Q3: 7,111,596 shares; 2025Q4: 7,111,596 shares; 2026Q1: 6,481,085 shares; 2026Q2: 6,007,834 shares 6,007,834$801M19.24%-473,251Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 10,736,000 shares; 2025Q1: 10,736,000 shares; 2025Q2: 10,736,000 shares; 2025Q3: 8,536,196 shares; 2025Q4: 12,762,094 shares; 2026Q1: 10,531,071 shares; 2026Q2: 9,081,201 shares 9,081,201$284M6.82%-1,449,870Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,670,206 shares; 2024Q4: 3,670,206 shares; 2025Q1: 3,670,206 shares; 2025Q2: 3,670,206 shares; 2025Q3: 3,670,206 shares; 2025Q4: 3,670,206 shares; 2026Q1: 3,670,206 shares; 2026Q2: 3,670,206 shares 3,670,206$261M6.27%0Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 6,964,375 shares; 2024Q4: 6,964,375 shares; 2025Q1: 6,964,375 shares; 2025Q2: 6,964,375 shares; 2025Q3: 6,798,162 shares; 2025Q4: 5,868,162 shares; 2026Q1: 4,946,894 shares; 2026Q2: 4,854,436 shares 4,854,436$188M4.52%-92,458Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,660,933 shares; 2026Q1: 4,457,988 shares; 2026Q2: 4,457,988 shares 4,457,988$172M4.13%0Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,100,582 shares; 2025Q4: 1,900,582 shares; 2026Q1: 1,900,582 shares; 2026Q2: 1,900,582 shares 1,900,582$169M4.06%0Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 1,501,624 shares; 2025Q1: 1,501,624 shares; 2025Q2: 1,501,624 shares; 2025Q3: 1,676,624 shares; 2025Q4: 1,676,624 shares; 2026Q1: 1,676,624 shares; 2026Q2: 1,676,624 shares 1,676,624$163M3.93%0Timeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 62,049 shares; 2026Q1: 1,062,049 shares; 2026Q2: 1,062,049 shares 1,062,049$124M2.99%0Timeline
ZLABZAI LAB LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 6,137,627 shares 6,137,627$117M2.8%newTimeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 4,643,812 shares; 2024Q4: 4,643,812 shares; 2025Q1: 5,943,812 shares; 2025Q2: 5,943,812 shares; 2025Q3: 6,243,812 shares; 2025Q4: 6,243,812 shares; 2026Q1: 6,243,812 shares; 2026Q2: 6,243,812 shares 6,243,812$112M2.7%0Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 4,622,151 shares; 2026Q1: 4,622,151 shares; 2026Q2: 4,622,151 shares 4,622,151$112M2.69%0Timeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 11,020,968 shares; 2026Q2: 11,020,968 shares 11,020,968$110M2.65%0Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 5,673,078 shares; 2026Q2: 5,673,078 shares 5,673,078$104M2.51%0Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,989,103 shares; 2024Q4: 1,989,103 shares; 2025Q1: 2,898,103 shares; 2025Q2: 2,898,103 shares; 2025Q3: 2,898,103 shares; 2025Q4: 2,898,103 shares; 2026Q1: 3,248,980 shares; 2026Q2: 3,248,980 shares 3,248,980$104M2.49%0Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,650,150 shares; 2024Q4: 2,650,150 shares; 2025Q1: 2,650,150 shares; 2025Q2: 3,766,660 shares; 2025Q3: 4,615,144 shares; 2025Q4: 4,615,144 shares; 2026Q1: 4,615,144 shares; 2026Q2: 4,615,144 shares 4,615,144$103M2.46%0Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 486,957 shares; 2024Q4: 486,957 shares; 2025Q1: 465,257 shares; 2025Q2: 465,257 shares; 2025Q3: 465,257 shares; 2025Q4: not reported; 2026Q1: 1,341,862 shares; 2026Q2: 1,341,862 shares 1,341,862$98.1M2.36%0Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,810,351 shares; 2025Q4: 3,220,186 shares; 2026Q1: 4,273,356 shares; 2026Q2: 4,273,356 shares 4,273,356$80M1.92%0Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 12,362,205 shares; 2024Q4: 12,362,205 shares; 2025Q1: 12,362,205 shares; 2025Q2: 12,362,205 shares; 2025Q3: 12,362,205 shares; 2025Q4: 12,362,205 shares; 2026Q1: 12,362,205 shares; 2026Q2: 12,362,205 shares 12,362,205$76.2M1.83%0Timeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 9,533,333 shares 9,533,333$67.7M1.63%newTimeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 436,473 shares; 2025Q4: 436,473 shares; 2026Q1: 576,473 shares; 2026Q2: 340,899 shares 340,899$63.8M1.53%-235,574Timeline
TRAXFIRST TRACKS BIOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,895,304 shares 2,895,304$58.3M1.4%newTimeline
KODKODIAK SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,008,158 shares; 2024Q4: 1,145,538 shares; 2025Q1: 1,145,538 shares; 2025Q2: 1,145,538 shares; 2025Q3: 1,145,538 shares; 2025Q4: 1,445,538 shares; 2026Q1: 1,445,538 shares; 2026Q2: 1,445,538 shares 1,445,538$56.3M1.35%0Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 483,000 shares; 2024Q4: 483,000 shares; 2025Q1: 483,000 shares; 2025Q2: 483,000 shares; 2025Q3: 483,000 shares; 2025Q4: 483,000 shares; 2026Q1: 738,383 shares; 2026Q2: 3,017,120 shares 3,017,120$55.8M1.34%+2,278,737Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,745,016 shares; 2025Q4: 1,745,015 shares; 2026Q1: 1,839,489 shares; 2026Q2: 1,447,310 shares 1,447,310$47M1.13%-392,179Timeline
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 17,754,430 shares; 2026Q2: 17,754,430 shares 17,754,430$43.4M1.04%0Timeline
TECXTECTONIC THERAPEUTIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,204,891 shares; 2026Q2: 1,204,891 shares 1,204,891$41.4M1%0Timeline
XNCRXENCOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,427,138 shares; 2024Q4: 2,452,138 shares; 2025Q1: 2,452,138 shares; 2025Q2: 2,452,138 shares; 2025Q3: 2,452,138 shares; 2025Q4: 2,452,138 shares; 2026Q1: 2,452,138 shares; 2026Q2: 2,452,138 shares 2,452,138$39.5M0.95%0Timeline
SRZNSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,473,101 shares; 2026Q2: 1,473,101 shares 1,473,101$38.2M0.92%0Timeline
EDITEDITAS MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 11,111,111 shares 11,111,111$36M0.87%newTimeline
MBXMBX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 650,000 shares; 2024Q4: 650,000 shares; 2025Q1: 650,000 shares; 2025Q2: 650,000 shares; 2025Q3: 650,000 shares; 2025Q4: 650,000 shares; 2026Q1: 650,000 shares; 2026Q2: 650,000 shares 650,000$35.9M0.86%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,008,229 shares 1,008,229$34.9M0.84%newTimeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,033,560 shares; 2024Q4: 3,033,560 shares; 2025Q1: 3,033,560 shares; 2025Q2: 3,033,560 shares; 2025Q3: 3,033,560 shares; 2025Q4: 3,033,560 shares; 2026Q1: 3,033,560 shares; 2026Q2: 3,033,560 shares 3,033,560$33.3M0.8%0Timeline
IFRXINFLARX NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 14,500,000 shares 14,500,000$32.5M0.78%newTimeline
ALTALTIMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 10,000,000 shares 10,000,000$30.4M0.73%newTimeline
JANXJANUX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,789,617 shares; 2026Q1: 1,789,617 shares; 2026Q2: 1,789,617 shares 1,789,617$27.5M0.66%0Timeline
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 7,915,567 shares; 2026Q2: 7,915,567 shares 7,915,567$27M0.65%0Timeline
AGMBAGOMAB THERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,053,233 shares; 2026Q2: 2,053,233 shares 2,053,233$26.7M0.64%0Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 4,631,317 shares; 2026Q1: 4,631,317 shares; 2026Q2: 1,779,952 shares 1,779,952$26.5M0.64%-2,851,365Timeline
AKTSAKTIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 696,560 shares 696,560$22.5M0.54%newTimeline
ALECALECTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 10,000,000 shares; 2026Q1: 10,000,000 shares; 2026Q2: 10,000,000 shares 10,000,000$20.1M0.48%0Timeline
FBRXFORTE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 920,000 shares 920,000$19.6M0.47%newTimeline
MNPRMONOPAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 153,000 shares; 2025Q4: 141,915 shares; 2026Q1: 132,103 shares; 2026Q2: 203,327 shares 203,327$18.8M0.45%+71,224Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 5,319,148 shares; 2024Q4: 5,319,148 shares; 2025Q1: 5,319,148 shares; 2025Q2: 5,319,148 shares; 2025Q3: 6,117,232 shares; 2025Q4: 5,740,231 shares; 2026Q1: 1,647,752 shares; 2026Q2: 1,647,752 shares 1,647,752$16.2M0.39%0Timeline
ADCTADC THERAPEUTICS SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,390,175 shares; 2025Q4: 11,390,175 shares; 2026Q1: 11,390,175 shares; 2026Q2: 11,390,175 shares 11,390,175$12.2M0.29%0Timeline
ALXOALX ONCOLOGY HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 13,011,849 shares; 2026Q2: 5,655,487 shares 5,655,487$11.7M0.28%-7,356,362Timeline
TRDAENTRADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 584,955 shares; 2024Q4: 584,955 shares; 2025Q1: 584,955 shares; 2025Q2: 584,955 shares; 2025Q3: 584,955 shares; 2025Q4: 2,088,392 shares; 2026Q1: 2,287,500 shares; 2026Q2: 1,060,230 shares 1,060,230$7.8M0.19%-1,227,270Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 406,786 shares; 2026Q2: 406,786 shares 406,786$7.41M0.18%0Timeline
ARVNARVINAS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,617,365 shares; 2025Q4: 2,666,216 shares; 2026Q1: 2,387,461 shares; 2026Q2: 707,098 shares 707,098$5.88M0.14%-1,680,363Timeline
KRROKORRO BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 416,301 shares; 2025Q4: 416,301 shares; 2026Q1: 416,301 shares; 2026Q2: 416,301 shares 416,301$5.49M0.13%0Timeline
RACCRESEARCH ALLIANCE CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 500,000 shares 500,000$5.35M0.13%newTimeline
LONALEONABIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 464,398 shares; 2026Q1: 464,398 shares; 2026Q2: 464,398 shares 464,398$4.27M0.1%0Timeline
JATTJATT II ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 200,000 shares 200,000$2.27M0.05%newTimeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,682,696 shares; 2026Q2: 2,682,696 shares 2,682,696$1.49M0.04%0Timeline
EIKNEIKON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 37,902 shares 37,902$495K0.01%newTimeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CNTACENTESSA PHARMACEUTICALS PLC4,286,480$170Mshares
FULCFULCRUM THERAPEUTICS INC5,250,000$40.3Mshares
LQDALIQUIDIA CORPORATION403,048$15.2Mshares
URGNUROGEN PHARMA LTD405,365$7.29Mshares
GPCRSTRUCTURE THERAPEUTICS INC140,411$6.77Mshares
UPBUPSTREAM BIO INC181,063$1.63Mshares
VTGNVISTAGEN THERAPEUTICS INC2,676,580$1.53Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001214659-26-010290 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001214659-26-010290 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001214659-26-006367 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001214659-26-001871 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001214659-25-016751 Quarter ended 2025-09-302025-11-17acceptance time not in the bulk data set
13F-HR 0001214659-25-012291 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001214659-25-007553 Quarter ended 2025-03-312025-05-14acceptance time not in the bulk data set
13F-HR 0001214659-25-002888 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001214659-24-019064 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001214659-24-014472 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0001214659-24-009128 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0001214659-24-002612 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001214659-23-014945 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0001214659-23-011170 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0001214659-23-007097 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0001214659-23-002234 Quarter ended 2022-12-312023-02-14acceptance time not in the bulk data set
13F-HR 0001214659-22-013609 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0001214659-22-010118 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0001214659-22-007035 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0001214659-22-002872 Quarter ended 2021-12-312022-02-18acceptance time not in the bulk data set